Table 2.
Description of patients treated with rituximab, including previous immunosuppressive therapy
| Patient number | Age | M/F | Diagnosis | Year of diagnosis | HRCT diagnosis | Medication Pre-rituximab |
|---|---|---|---|---|---|---|
| 1 | 69 | M | RA | 2013 | UIP | azathioprine, prednisone |
| 2 | 67 | M | RA | 2010 | UIP | prednisone, cyclofosfamide, azathioprine |
| 3 | 65 | M | RA | 2013 | NSIP | cyclofosfamide, methotrexate |
| 4 | 44 | M | ASS | 2012 | UIP | prednisone, azathioprine |
| 5 | 57 | F | ASS | 2015 | fNSIP | prednisone, azathioprine |
| 6 | 69 | F | ASS | 2009 | fNSIP | prednisone, azathioprine |
| 7 | 59 | F | cEAA | 2015 | EAA | azathioprine, cyclofosfamide |
| 8 | 63 | F | cEAA | 2015 | EAA | cyclofosfamide, prednisone |
| 9 | 57 | M | Scleroderma | 2014 | fNSIP | cyclofosfamide, imuran |
| 10 | 69 | F | Connective tissue disease | 2010 | fNSIP | cyclofosfamide, prednisone |
Rheumatic arthritis (RA), antisynthetase syndrome (ASS), chronic extrinsic allergic alveolitis (cEAA), usual interstitial pneumonia (UIP), fibrotic (f) non-specific interstitial pneumonia (NSIP).